Food and Drug Administration (FDA) is warning retail pharmacies, health care professionals, wholesalers, and patients to check their Ozempic® (semaglutide) products’ lot and serial numbers to avoid purchasing counterfeit versions. Products with the lot number NAR0074 and serial number 430834149057 should not be used or distributed. FDA testing revealed that the needles in the sampled products are counterfeit and present an increased risk of infection for patients, as their sterility cannot be confirmed. Furthermore, other counterfeit parts of the sampled product include the pen label, health care professional and patient information, and carton. To date, the administration is aware of five adverse reactions from this specific illicit product, and they are common side effects associated with authentic Ozempic, which are nausea, abdominal pain, vomiting, constipation, and diarrhea. Retail pharmacies are advised to purchase genuine Ozempic from Novo Nordisk’s list of authorized distributors and to check the legitimacy of their shipments by reviewing the photographs and information on the products. For reference, images of authentic and illegitimate versions of Ozempic are available on FDA’s website.